Lund, Sweden, 27 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company’s candidate drug NeuroSTAT, in development for treatment of moderate to s ...

Lund, Sweden, 4 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study wit ...

Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive’s IND (Investigational ...

Lund, 30 April, 2019— NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the Supreme Court had delivered its ruling concerning arbitration between NeuroVive and Cic ...

Lund, Sweden, 19 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company’s KL1333 phase Ia/b study has been screen ...

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.

Lund, 15 November, 2018- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in ...

Lund, Sweden, 10 October 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned p ...